Previous close | 22.84 |
Open | 23.50 |
Bid | 24.20 x 100 |
Ask | 24.37 x 100 |
Day's range | 22.77 - 25.91 |
52-week range | 9.26 - 26.70 |
Volume | |
Avg. volume | 234,025 |
Market cap | 671.194M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.11 |
FRIENDSWOOD, Texas, May 03, 2024--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
Comprehensive Analysis of Castle Biosciences' First Quarter Financial Performance
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 75.68% and 6.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?